 | | Vol. 8.26 – 29 August, 2022 |
| |
|
|
| The authors reported KLF5 specifically marked the epidermis, and that its deletion led to skin barrier dysfunction in vivo.
[Genes & Development] |
|  | | PUBLICATIONSRanked by the impact factor of the journal |
| | DERMAL STEM CELLS & TISSUE REGENERATION |
|
|
|
| Zinc alginate hydrogel embedded with hollow dopamine nanoparticles exhibited no obvious toxicity against keratinocytes, human umbilical vein endothelial cells, human skin fibroblasts, and mice.
[Materials & Design] |
|
|
|
| Researchers investigated the effect of miR-100-5p, one of the most abundant microRNAs in exosomes from human adipose-derived stem cells, on the proliferation of human epidermal stem cells.
[Stem Cells International] |
|
|
|
| Investigators characterized the rat epidermal keratinocyte organotypic culture model by structural comparison to native human and rat skin and by investigating functional characteristics of lipid packing, polarity, and permeability coefficients.
[European Journal of Pharmaceutical Sciences] |
| |
|
|
| The authors showed that knockdown of DUSP1 or DUSP8 or treatment with BCI – a pharmacological inhibitor of DUSP1/6 – decreased the survival of MAPKi-resistant cells and sensitizes them to BRAFi and MEKi.
[Scientific Reports] |
|
|
|
| The role of spermidine (SPD) in melanogenesis was investigated, showing potential as a pigmenting agent. SPD treatment increased melanin production in melanocytes in a dose dependent manner.
[Scientific Reports] |
|  |
|
|
|
| Researchers summarize the recent progress of the protective function of protein tyrosine phosphatases in epidermal photocarcinogenesis.
[Photochemistry and Photobiology] |
|
|
|
|
| Hadlima, developed by South Korea-based biotech firm Samsung Bioepis and to be commercialized by global healthcare company Organon, became the latest medication to gain the approval of the FDA for the treatment of several disorders, including arthritis, ulcerative colitis, and plaque psoriasis.
[Humira (Medical News Today)] |
|
|
|
| Iovance Biotherapeutics, Inc., has initiated a rolling BLA submission to the US FDA for lifileucel, a tumor infiltrating lymphocyte therapy, in patients with advanced melanoma.
[Iovance Biotherapeutics] |
|
|
|
|
| December 5 – 7, 2022
Virtual |
|
|
|
|
|
| | Olivia Newton-John Cancer Research Institute – Victoria, Australia |
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
| | The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
| | Melanoma Institute Australia – Sydney, Australia |
|
|
|
| | Lehigh University – Bethlehem, Pennsylvania, Untied States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
